Data gathered: April 1
AI Stock Analysis - Karyopharm Therapeutics (KPTI)
Analysis generated January 31, 2025. Powered by Chat GPT.
Karyopharm Therapeutics Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company's leading product, XPOVIO (selinexor), is an oral Selective Inhibitor of Nuclear Export (SINE) compound. The company's headquarters is in Newton, Massachusetts.
Stock Alerts - Karyopharm Therapeutics (KPTI)
 |
Karyopharm Therapeutics | April 1 Price is down by -5.9% in the last 24h. |
|
Karyopharm Therapeutics | March 31 Price is down by -5.1% in the last 24h. |
|
Karyopharm Therapeutics | March 28 Price is down by -5.5% in the last 24h. |
|
Karyopharm Therapeutics | March 27 Price is down by -7.2% in the last 24h. |
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 879 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 67 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,850 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,546 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 71 | Sign up | Sign up | Sign up |
| Linkedin Employees | 364 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $3.54 |
| Target Price | Sign up |
| Volume | 149,210 |
| Market Cap | $31M |
| Year Range | $3.54 - $15.9 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200 Day Moving Average – Time to Sell?March 25 - ETF Daily News |
|
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell?March 11 - ETF Daily News |
|
Robert W. Baird Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $54.00March 4 - ETF Daily News |
|
Karyopharm Therapeutics (KPTI) Projected to Post Earnings on ThursdayMarch 4 - ETF Daily News |
|
Q1 EPS Estimate for Karyopharm Therapeutics Cut by AnalystMarch 2 - ETF Daily News |
|
Karyopharm Therapeutics (NASDAQ:KPTI) Sees Unusually-High Trading Volume After Analyst UpgradeFebruary 28 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 39M | 28M | 11M | -32M | -21M | -0.257 |
| Q2 '24 | 87M | 31M | 56M | 24M | 33M | 0.150 |
| Q1 '24 | 27M | 30M | -2.3M | -37M | -31M | -0.320 |
| Q4 '23 | 28M | 31M | -3.1M | -42M | -35M | -0.360 |
| Q3 '23 | 30M | 31M | -870,000 | -35M | -28M | -0.300 |
Insider Transactions View All
| Abate Kristin filed to sell 9,713 shares at $6.3. March 6 '25 |
| Mano Michael filed to sell 21,047 shares at $6.3. March 6 '25 |
| Poulton Stuart filed to sell 27,414 shares at $6.3. March 6 '25 |
| Rangwala Reshma filed to sell 29,272 shares at $6.3. March 6 '25 |
| Cheng Sohanya Roshan filed to sell 34,314 shares at $6.3. March 6 '25 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $31M.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $3.54.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.